New Data Challenges Old Beliefs in Early Breast Cancer Risk Assessment

IRVINE, CA – April 30, 2026 – New research set to be unveiled at a major European oncology conference is poised to challenge fundamental assumptions about how doctors assess risk in early-stage breast cancer. Agendia, a leader in precision oncology, has announced it will present data that not only identifies a previously hidden high-risk group among patients thought to be safe but also uncovers a paradoxical link between body weight and cancer recurrence.

The findings, scheduled for presentation at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin next month, stem from two separate analyses involving the company's MammaPrint and BluePrint genomic tests. One study suggests that tumor size, a long-standing pillar of cancer staging, may be a less reliable indicator of danger than the tumor's underlying biology. The other introduces a counter-intuitive wrinkle into the complex relationship between obesity and cancer outcomes, promising to spark debate and new avenues of investigation.

Unmasking a Hidden Threat in 'Low-Risk' Tumors

For decades, a small, node-negative tumor has often been a sign of a favorable prognosis, giving both patient and physician a degree of confidence. However, forthcoming data from the large, prospective FLEX Study suggests this view may be dangerously oversimplified.

In a retrospective analysis of 4,349 patients with small tumors that had not spread to the lymph nodes (T1N0), Agendia's 70-gene MammaPrint test identified a distinct subgroup with unexpectedly aggressive biology. This group, classified as "High Risk 2" (H2), accounted for 10% of the total patient cohort. Despite their small tumor size, these patients faced significantly worse outcomes.

The data reveals that patients with H2 tumors had a 3-year recurrence-free survival rate of 93%, compared to 98% for patients whose tumors were classified as Low or UltraLow Risk. The gap was even more pronounced within the most common form of breast cancer, HR+HER2- disease, where the H2 group's survival rate dropped to 91%.

"These findings highlight the prognostic value of MammaPrint in small, node-negative breast cancers," said William Audeh, MD, Chief Medical Officer of Agendia, in a statement. “While this group of patients are generally regarded as having a favorable prognosis, our data reveal a distinct subset with high-risk biology who may benefit from escalated therapy and biology-informed treatment approaches that might have otherwise been overlooked based on tumor size alone."

This evidence reinforces a paradigm shift in oncology: moving away from relying solely on anatomical features like tumor size and toward a deeper understanding of the genetic drivers of a cancer. For the subset of patients identified as H2, this could mean the difference between receiving a potentially life-saving escalated treatment and being undertreated based on outdated assumptions.

The Growing Role of Genomics in the Clinic

Agendia's findings are part of a broader movement in cancer care that leverages genomic profiling to personalize treatment. Assays like MammaPrint, which is FDA-cleared, and its main competitor, the Oncotype DX test, analyze the activity of specific genes within a tumor to predict its future behavior. This information provides crucial guidance for oncologists wrestling with one of the most common dilemmas in early-stage breast cancer: whether to recommend adjuvant chemotherapy.

For many patients, genomic testing has been instrumental in safely de-escalating treatment, allowing them to avoid the toxic side effects of chemotherapy when their tumor's biology indicates a low risk of recurrence. The new FLEX data highlights the other side of that coin: the critical importance of identifying high-risk patients who might otherwise be missed by traditional staging. By demonstrating its ability to find risk in a population often considered uniformly low-risk, MammaPrint may be carving out a key area of differentiation in a competitive diagnostics market.

Experts note that integrating these biological insights is essential for true precision medicine. It allows for a more tailored approach where treatment intensity is matched to the tumor's specific molecular profile, not just its physical size. As more real-world evidence from large studies like FLEX emerges, the use of such genomic tools is expected to become even more standard in clinical guidelines worldwide.

A Surprising Twist on Body Weight and Cancer Risk

While the FLEX data offers a clear path toward refining clinical practice, a second presentation from Agendia is set to open a new, more complex line of scientific inquiry. An exploratory analysis of the landmark MINDACT trial—the very study that cemented the role of MammaPrint in guiding chemotherapy decisions—has yielded a perplexing result concerning body mass index (BMI).

Contrary to a large body of existing research that links obesity with worse breast cancer outcomes, this analysis found that in a cohort of patients with ER+/HER2- disease, those with obesity actually had a lower risk of distant metastasis compared to their normal-weight counterparts. This finding, sometimes referred to as an "obesity paradox," has been observed in other cancer types but remains highly controversial and poorly understood.

This non-linear relationship challenges the simple narrative that higher BMI is always detrimental. The analysis, co-authored by MammaPrint inventor Dr. Laura van 't Veer, is described as exploratory, and experts caution that it is far from being a recommendation for clinical practice. Instead, it is a powerful call for more research. Scientists will now need to investigate the potential biological mechanisms that could explain such a counter-intuitive result. Factors like hormone levels, chronic inflammation, metabolic pathways, and interactions with specific cancer treatments could all play a role in this complex interplay.

Charting the Future of Personalized Breast Cancer Care

Taken together, the two upcoming ESMO presentations paint a vivid picture of the current state of breast cancer research. On one hand, clinical tools are becoming sharper and more refined, capable of uncovering risk in ever more granular detail. The MammaPrint data from the FLEX study provides actionable information that could influence treatment decisions for a specific patient group in the near future.

On the other hand, the science continues to reveal layers of biological complexity that defy easy explanation, as seen in the MINDACT BMI analysis. This finding underscores that as medicine becomes more personalized, it must also account for a host of interconnected factors that influence a patient's journey.

As oncologists and researchers gather in Berlin, the discussions will likely center on how to best integrate this new knowledge. The immediate impact will be a renewed focus on the biology of seemingly low-risk tumors, while the long-term quest will be to unravel the intricate connections between a patient's metabolism, their cancer's genetics, and their ultimate outcome.